Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of diterpene ginkgolide meglumine injection in convalescent cerebral infarction and hemorheology

Weiwei Gao¹, Defa Zhu²

¹General Medicine Department III, Anhui Second People's Hospital Huangshan Road Hospital District, No. 199, Huangshan Road, Baohe District, China; ²Department of Endocrinology for the Elderly, First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Shushan District, Hefei City, Anhui Province, China.

For correspondence:- Defa Zhu Email: Zhudefa_ah66@hotmail.com

Accepted: 7 May 2024 Published: 29 May 2024

Citation: Gao W, Zhu D. Efficacy of diterpene ginkgolide meglumine injection in convalescent cerebral infarction and hemorheology. Trop J Pharm Res 2024; 23(5):881-886 doi: 10.4314/tjpr.v23i5.10

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of diterpene ginkgolide meglumine injection (DGMI) compared to betahistine in convalescent cerebral infarction (CI).

Methods: 80 convalescent patients with CI from March 2021 and March 2022 were randomly grouped into control and study groups comprising 40 participants each. Control and study groups received 20 mg betahistine and 25 mg DGMI respectively in 250 mL normal saline for 1 week. The efficacy, National Institute of Health Stroke Scale (NIHSS) score, hemorheology, and adverse effects were investigated in control and study groups

Results: Total effective rate was significantly higher in study group compared to control group (p < 0.05). Also, the National Institute of Health Stroke Scale (NIHSS) score, plasma viscosity (PV), whole blood reduced viscosity, fibrinogen (FIB), erythrocyte aggregation index (EAI), and incidence of adverse effect were significantly lower in study group compared to control group (p < 0.05).

Conclusion: Administration of DGMI to patients in the recovery period of CI improves neurological deficit, and average blood flow velocity in the brain, and reduces the incidence of adverse effects. Further studies with larger sample sizes and multi-center approaches will be required to validate these findings.

Keywords: Diterpene ginkgolide meglumine injection, Cerebral infarction recovery period, Clinical efficacy, Hemorheology